PMID- 29512462
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1875-5631 (Electronic)
IS  - 1566-5232 (Linking)
VI  - 18
IP  - 1
DP  - 2018
TI  - Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and 
      Susceptibility to Schizophrenia, Parkinson's and Alzheimer's Diseases.
PG  - 45-63
LID - 10.2174/1566523218666180302163029 [doi]
AB  - Brain-Derived Neurotrophic Factor (BDNF) is a dominant neurotrophic factor in the 
      brain which plays a crucial role in differentiation, regeneration and plasticity 
      mechanisms. Binding of the BDNF to its high-affinity Tropomyosin-related kinase B 
      (TrkB) receptor leads to phosphorylation of TrkB, thus activating the three 
      important downstream intracellular signaling cascades within the neural cells 
      including phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), 
      Phospholipase C-gamma (PLCgamma), and mitogen-activated protein kinase/extracellular 
      signal-related kinase (MAPK/ERK) pathways. Transcription of these pathways is 
      regulated by cAMP Response Element-Binding protein (CREB) transcription factor, 
      which can upregulate gene expression. In this review, we attempted to explore the 
      role of BDNF and its associated pathways in susceptibility to Schizophrenia 
      (Scz), Alzheimer's (AD), and Parkinson's (PD) diseases. Furthermore, we discuss 
      dysfunction in BDNF signaling pathway and the therapeutic potential of BDNF in 
      the treatment of these disorders. The review covers various therapeutic 
      strategies including BDNF gene therapy, transplantation of BDNFexpressing cell 
      grafts, epigenetic manipulation, and intraparenchymal BDNF protein infusion as 
      well. This review seeks to achieve these goals by reviewing recent studies on 
      BDNF and examining the details of BDNF pathway in any of the above-mentioned 
      diseases.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Mohammadi, Alireza
AU  - Mohammadi A
AD  - Neuroscience Research Center, Baqiyatallah University of Medical Sciences, 
      Tehran, Iran.
FAU - Amooeian, Vahid Ghasem
AU  - Amooeian VG
AD  - Students; Scientific Research Center (SSRC), Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Rashidi, Ehsan
AU  - Rashidi E
AD  - Students; Scientific Research Center (SSRC), Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Gene Ther
JT  - Current gene therapy
JID - 101125446
RN  - 0 (Brain-Derived Neurotrophic Factor)
SB  - IM
MH  - Alzheimer Disease/*genetics/metabolism/therapy
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*genetics/metabolism
MH  - Gene Transfer Techniques
MH  - Genetic Therapy/methods
MH  - Humans
MH  - Parkinson Disease/*genetics/metabolism/therapy
MH  - *Polymorphism, Genetic
MH  - Schizophrenia/*genetics/metabolism/therapy
MH  - Signal Transduction/*genetics
OTO - NOTNLM
OT  - BDNF
OT  - Gene delivery
OT  - MAPK/ERK
OT  - PI3K/AKT
OT  - PLCgamma
OT  - Susceptibility.
EDAT- 2018/03/08 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/03/08 06:00
PHST- 2017/11/10 00:00 [received]
PHST- 2018/01/27 00:00 [revised]
PHST- 2018/02/27 00:00 [accepted]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
AID - CGT-EPUB-88899 [pii]
AID - 10.2174/1566523218666180302163029 [doi]
PST - ppublish
SO  - Curr Gene Ther. 2018;18(1):45-63. doi: 10.2174/1566523218666180302163029.